10-Q · May 14, 2026
eXoZymes remained in a challenging financial position for the quarter ended March 31, 2026. The company reported no revenue and a net loss of $2.37 million, representing a substantial increase in losses compared to the…
Earnings analysis · 10-Q
EXOZ earnings analysis
Filed August 13, 2026 · Our reading of the company's report
The latest report
The supplied 10-Q text does not include the income statement, balance sheet, cash-flow statement, or segment disclosures, so revenue, margins, EPS, cash flow, and working-capital trends cannot be quantified. The primary…
Read full summary
The supplied 10-Q text does not include the income statement, balance sheet, cash-flow statement, or segment disclosures, so revenue, margins, EPS, cash flow, and working-capital trends cannot be quantified. The primary developments are substantial doubt about continuing as a going concern, with working capital insufficient for 12 months as of June 30, 2026, and disclosure controls remaining ineffective. Management is pursuing remediation and additional funding, but no committed financing sources or quantitative guidance were provided.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
Internal-control remediation underway
Management redesigned the financial reporting process and stated that the remediation changes are expected to materially improve internal controls. The remediation effort was ongoing as of June 30, 2026.
-
Financial statements affirmed under GAAP
The company stated that its condensed unaudited consolidated financial statements for the periods covered by the report fairly state its financial position, results of operations, and cash flows in conformity with GAAP, despite the control weaknesses.
-
No material litigation reported
The company reported no material legal proceedings and no known pending or threatened litigation expected to materially affect the business, operating results, cash flows, or financial condition.
What to watch
-
Going-concern uncertainty
Management concluded that substantial doubt exists regarding the company’s ability to continue as a going concern because existing working capital is insufficient to fund operations for 12 months from issuance of the financial statements as of June 30, 2026.
-
Dependence on additional financing
The company has no committed sources of additional financing and may need additional offerings, financing, grants, or intellectual-property transactions. Management specifically stated that funding may not be available on commercially reasonable terms, if at all.
-
Tariff and research-funding exposure
The filing added risks from U.S. tariff and import/export policy changes, noting that these developments could restrict suppliers, customers, research grants, and investor funding. The disclosure references significant policy actions beginning in early 2025 and states that the full impact has not yet been realized.
-
Material control weakness persists
Management concluded that disclosure controls and procedures were not effective at the reasonable-assurance level as of June 30, 2026, due to previously identified material weaknesses. The weaknesses will not be considered remediated until controls operate effectively for a sufficient period and management completes testing.
Management's outlook
No quantitative revenue or EPS outlook was provided in the supplied 10-Q text; outlook appears deferred to a separate earnings release or call.
Earlier filings 4
10-K · March 30, 2026
eXoZymes positions itself as a platform company building AI‑designed, cell‑free “exozymes” to produce high‑value small molecules with an initial 2026–2027 commercialization focus on nutraceuticals that may later convert…
10-Q · May 12, 2025
eXoZymes reported no revenue for the quarter and a widening net loss of $1,856,421 (Q1 2025) vs $1,008,458 (Q1 2024), driving EPS to $(0.22) from $(0.16). Cash declined to $8,511,477 as of March 31, 2025 (down…
10-K · March 31, 2025
eXoZymes (formerly Invizyne) is an early-stage platform company commercializing AI‑designed, cell‑free “exozymes” for biomanufacturing of high‑value small molecules. The filing emphasizes an initial commercial focus on…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.